A number of brokerages have weighed in on ICPT. Liberum Capital maintained the stock with "Sell" rating in Tuesday, February 2 report.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has a beta of -1.92, compared to a beta of 1 for the market, which implies that the stock's price movements are less extreme than the market as a whole. For the quarter, shares have been noted at 16.13%. They set a "buy" rating and a $275.00 price target for the company.
Among 15 analysts covering EnQuest Plc (LON:ENQ), 3 have Buy rating, 4 Sell and 8 Hold. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $189.00 on company shares.
News headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive recently, Accern Sentiment reports.
Company shares last traded at $97.30 significantly below the 50 day moving average of $112.57 and well below the 200 day moving average of $117.15. Over the past month the firm's stock is 12.22%, -3.81% for the last quarter, -11.21% for the past six-months and -21.92% for the a year ago.
Why to Observe Volume of Intercept Pharmaceuticals, Inc. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Return on Equity (ROE) stands at -135.2% and Return on Investment (ROI) of -61.3 percent. The company's revenue was up 459.6% on a year-over-year basis. Next quarter's EPS is forecasted to be $-3.44 with next year's EPS anticipated to be $-11.57. On average, analysts expect that Intercept Pharmaceuticals, Inc. will post ($14.05) earnings per share for the current fiscal year.
China, Russia warn U.S. against government change in North Korea
Pyongyang has staged a series of missile tests in recent months that appeared to bring much of the USA mainland into range. Those actions, regularly dismissed as insufficient by Trump's administration, have led to public spats with Pyongyang.
TRADEMARK VIOLATION NOTICE: "Intercept Pharmaceuticals, Inc". Citigroup has invested 0.01% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). If you are viewing this story on another publication, it was copied illegally and republished in violation of U.S. & global trademark and copyright legislation. Morgan Stanley upgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rating on Friday, January 29. During the trading on 09/12/2017, Company's stock ranged from $6.18 to $6.54. The shares were sold at an average price of $113.60, for a total value of $28,286.40. Insiders own 9.20% of the company's stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
On Monday, July 3rd, David Shapiro sold 350 shares of Intercept Pharmaceuticals stock. The shares were sold on August 25th for an average price of $111.32. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company's stock valued at $118,000 after purchasing an additional 132 shares during the period. The disclosure for this sale can be found here.
Several hedge funds have recently added to or reduced their stakes in the business.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) shares are displaying elevated levels of volatility in today's session. Cowen and Company reiterated an outperform rating and issued a $225.00 price target on shares of Intercept Pharmaceuticals in a report on Friday. Intercept Pharmaceuticals earned a coverage optimism score of 0.24 on Accern's scale. The stock's market capitalization is $2.85 billion. Vanguard Group Inc. lifted its holdings in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. NY now owns 1,234 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 38 shares in the last quarter. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. WFG Advisors LP now owns 888 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 125 shares during the period. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.
To view ValuEngine's full report, visit ValuEngine's official website. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.